Clinical Trial Update: Assessment of Safety, Tolerability, Radiation Dosimetry, Imaging Properties of 89Zr-girentuximab in Patients With NMIBC [EARLY_Phase 1]

View source ↗

Summary

Early-phase study evaluating safety, tolerability, radiation dosimetry, and imaging properties of 89Zr-labeled girentuximab in patients with non-muscle-invasive…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• 89Zr-girentuximab (girentuximab)

Snippet

Sponsor: Institut Cancerologie de l'Ouest | Conditions: Bladder Cancer | EARLY_Phase 1 | Status: COMPLETED | Results posted: 2026-01-07